drugset / Trial / NCT00329927
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects
Non-randomizedSingle-groupOpen-labelPrevention
Summary
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over
Timeline
- Start
- 2006-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07 | Vaccine | — | — |